MedPage Today: Triple Combo Tx Durable for T2D

September 1, 2016

Starting newly-diagnosed diabetes patients on the triple combination of metformin/pioglitazone/exenatide upfront provided better glucose control with less hypoglycemia than a standard sequential regimen, 3-year follow-up from the EDICT trial showed. Read the full story at MedPage Today

UTSA Today: UTSA alumna’s medical device receives UT System investment

September 1, 2016

The UT Horizon Fund recently invested $150,000 to fund Cardiovate, a San Antonio-based startup that is using technology from two University of Texas System institutions to commercialize a medical device to treat vascular diseases by repairing blood vessels. Read the full story at UTSA Today

Undark Magazine: Rethinking Prostate Cancer Treatments

September 1, 2016

In an outcome likely to raise broad questions about aggressive prostate cancer treatment, a randomized study of 1,643 British men found that, roughly 10 years after a prostate cancer diagnosis, the vast majority of participants had survived the cancer regardless of whether they were treated with radiation, had their prostates surgically removed, or were simply […]

Laredo Morning Times: Veterans event will have on-site medical services, barbers, legal services

September 1, 2016

A first-time event, known as Stand Down for Homeless Veterans, was announced this week and plans are set to help address the needs of nearly 300 people in the four-hour service oriented session that begins at 9 a.m. and concludes at 1 p.m. on Sept. 20. Read the full story at the Laredo Morning Times

Street Insider: Akebia Therapeutics (AKBA) Reports Publication of Strong Vadadustat Phase 2 Data in CKD-Related Anemia

September 1, 2016

Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced the publication of positive results from a Phase 2b study of vadadustat, a once-daily oral HIF stabilizer, in development for the treatment of anemia related to chronic kidney disease (CKD). Read the full story at Street Insider


National Pain Report: New directions for painkiller research

August 31, 2016

Health Science Center study suggests targeting opioid receptors outside the brain to reduce side effects.